- Demand for accredited cannabis testing in California is at an all-time high
- Company enters long-term lease in the heart of Los Angeles
- Strategically positioned to capitalize on the largest market place in the United States
State mandated testing for California’s cannabis industry will allow only lab-tested cannabis products to be sold by licensed retailers beginning on July 1. There is a high probability that there won’t be enough labs in California to keep up with the testing requirements. This is positive news for existing labs, as demand will be high and possibly max out their capacity, creating a surge in the need for additional testing facilities.
EVIO Inc. (OTCQB: EVIO), a leading national provider of accredited cannabis testing and scientific research for the regulated cannabis industry, seeks to capitalize on this opportunity. EVIO Labs began with one lab in Oregon and now provides clients with superior customer service, reliable results and world-class expertise in California, Colorado, Florida, Massachusetts and Canada. The company recently announced further expansion of its testing services to the Southern California cannabis market, and it has entered a long-term lease for a 2,700 square foot facility in the heart of Los Angeles in the Mission Junction District. The company has plans to have 18 laboratory facilities in locations across North America by the end of 2018.
As California rolls out the July 1 state mandated testing deadline, the need for EVIO’s services is expected to increase significantly. “We are focused on positioning EVIO to capitalize on this tremendous growth by pursuing aggressive expansion,” EVIO CEO William Waldrop stated in a news release.
New Frontier Data projects the value of the California legal cannabis market at $1.9 billion in 2018 and forecasts an increase to $4.7 billion by 2025. EVIO’s expansion into Los Angeles strategically positions the company to capitalize on the largest cannabis market place in the United States.
For more information, visit the company’s website at www.EVIOLabs.com
More from CannabisNewsWire
About CBDWire
CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
[email protected]
